219 related articles for article (PubMed ID: 11720742)
1. Prognostic molecular markers in non-small cell lung cancer.
Nikliński J; Niklińska W; Laudanski J; Chyczewska E; Chyczewski L
Lung Cancer; 2001 Dec; 34 Suppl 2():S53-8. PubMed ID: 11720742
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
[TBL] [Abstract][Full Text] [Related]
3. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome.
Mishina T; Dosaka-Akita H; Kinoshita I; Hommura F; Morikawa T; Katoh H; Kawakami Y
Br J Cancer; 1999 Jun; 80(8):1289-95. PubMed ID: 10376986
[TBL] [Abstract][Full Text] [Related]
5. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.
Niklińska W; Burzykowski T; Chyczewski L; Nikliński J
Lung Cancer; 2001 Dec; 34 Suppl 2():S59-64. PubMed ID: 11720743
[TBL] [Abstract][Full Text] [Related]
6. Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.
Dragoj M; Milosevic Z; Bankovic J; Dinic J; Pesic M; Tanic N; Stankovic T
Tumour Biol; 2015 Nov; 36(11):8773-80. PubMed ID: 26055143
[TBL] [Abstract][Full Text] [Related]
7. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
[TBL] [Abstract][Full Text] [Related]
8. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
9. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.
Kim YC; Park KO; Kern JA; Park CS; Lim SC; Jang AS; Yang JB
Lung Cancer; 1998 Dec; 22(3):181-90. PubMed ID: 10048471
[TBL] [Abstract][Full Text] [Related]
10. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
11. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
12. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
[TBL] [Abstract][Full Text] [Related]
13. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
14. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
15. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.
Bennett WP; el-Deiry WS; Rush WL; Guinee DG; Freedman AN; Caporaso NE; Welsh JA; Jones RT; Borkowski A; Travis WD; Fleming MV; Trastek V; Pairolero PC; Tazelaar HD; Midthun D; Jett JR; Liotta LA; Harris CC
Clin Cancer Res; 1998 Jun; 4(6):1499-506. PubMed ID: 9626468
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
[TBL] [Abstract][Full Text] [Related]
17. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K
Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer.
Zhou JX; Niehans GA; Shar A; Rubins JB; Frizelle SP; Kratzke RA
Lung Cancer; 2001 Apr; 32(1):27-38. PubMed ID: 11282426
[TBL] [Abstract][Full Text] [Related]
20. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]